QURE

What's Next For uniQure Stock After A 13% Drop Last Week?

One Year Following Single Administration, UniQure's Hemophilia B Gene Therapy Candidate Shows Sustained Increase In Factor IX Levels

UniQure Expands Gene Therapies Pipeline For Neurological Disorders With Corlieve Acquisition

uniQure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE)

uniQure Announces Enrollment of First Two Patients in Second Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington's Disease

uniQure: Biding Time Turns To Buying Time

UPDATE -- uniQure to Participate in Multiple Upcoming Industry Conferences in June